Zong Zhuang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zong Zhuang has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Chun-Hua Hang
Department of Neurosurgery, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China
15 shared publications - Wei Li
Department of Neurosurgery, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China
11 shared publications - Yue Lu
Department of Neurosurgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
6 shared publications - Yong-Yue Gao
Department of Neurosurgery, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China
5 shared publications - Meng-Liang Zhou
Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210000, China
4 shared publications - Qi Zhu
Department of Neurosurgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008 Jiangsu, China
4 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7969
RETRACTED: Dai et al. Decreased Expression of CIRP Induced by Therapeutic Hypothermia Correlates with Reduced Early Brain Injury After Subarachnoid Hemorrhage. J. Clin. Med. 2022, 11, 3411
The journal retracts the article titled “Decreased expression of CIRP induced by therapeutic hypothermia correlates with reduced early brain injury after subarachnoid hemorrhage”
- 15 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7969
Open AccessRETRACTED: Dai et al. Decreased Expression of CIRP Induced by Therapeutic Hypothermia Correlates with Reduced Early Brain Injury After Subarachnoid Hemorrhage. J. Clin. Med. 2022, 11, 3411
The journal retracts the article titled “Decreased expression of CIRP induced by therapeutic hypothermia correlates with reduced early brain injury after subarachnoid hemorrhage”
- Open Access
- 10 April 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1790419
Perforator-sparing basilar artery reconstruction normalizes pathological hemodynamics in vertebrobasilar dolichoectasia: a CFD study
Background: Vertebrobasilar dolichoectasia (VBD) carries high risks of stroke and hemorrhage, yet current treatments remain suboptimal and often compromise critical pontine perforators (PPs). We used computational fluid dynamics (CFD) to evaluate a novel hemodynamically-guided, perforator-sparing reconstruction strategy. Methods: Patient-specific CFD models from 24 VBD patients were compared with 24 age-sex-matched controls and virtual post-intervention models simulating idealized partial anterior basilar artery (BA) lumen reduction to establish hemodynamic optimization targets while preserving posterior wall PPs. Transient simulations quantified pressure, velocity, time-averaged wall shear stress (TAWSS), oscillatory shear index (OSI), and relative residence time (RRT) within the BA and nine modeled PPs per case. Results: Untreated VBD exhibited pathological hemodynamics: elevated aneurysmal pressure (101.73 ± 0.28 vs. 100.59 ± 0.87 mmHg, p < 0.001), flow stasis (velocity: 5.53 ± 3.52 vs. 12.41 ± 3.44 cm/s, p < 0.001), reduced TAWSS (0.007 ± 0.004 vs. 0.03 ± 0.01 Pa, p < 0.001), and increased OSI (0.07 ± 0.04 vs. 0.01 ± 0.00) and RRT (12.73 ± 13.81 vs. 0.33 ± 0.11 /Pa, all p < 0.001). Perforator hemodynamics remained comparable to controls. Virtual reconstruction of BA normalized all aneurysmal parameters toward physiological levels (Post vs. Pre: all p < 0.001) without adversely affecting hemodynamics in the modeled PPs under the assumptions of the CFD framework. Strong correlations existed between BA volume and adverse hemodynamics, with therapeutic benefits approaching saturation at about 250 mm 3 . Conclusion: This in silico study demonstrates that perforator-sparing partial reconstruction can normalize VBD’s pathological hemodynamics without adversely affecting hemodynamics in the modeled PPs, and establishes a quantitative framework for future endovascular device development, though clinical translation requires validation through experimental models and prospective trials.
- 10 April 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1790419
Open AccessPerforator-sparing basilar artery reconstruction normalizes pathological hemodynamics in vertebrobasilar dolichoectasia: a CFD study
Background: Vertebrobasilar dolichoectasia (VBD) carries high risks of stroke and hemorrhage, yet current treatments remain suboptimal and often compromise critical pontine perforators (PPs). We used computational fluid dynamics (CFD) to evaluate a novel hemodynamically-guided, perforator-sparing reconstruction strategy. Methods: Patient-specific CFD models from 24 VBD patients were compared with 24 age-sex-matched controls and virtual post-intervention models simulating idealized partial anterior basilar artery (BA) lumen reduction to establish hemodynamic optimization targets while preserving posterior wall PPs. Transient simulations quantified pressure, velocity, time-averaged wall shear stress (TAWSS), oscillatory shear index (OSI), and relative residence time (RRT) within the BA and nine modeled PPs per case. Results: Untreated VBD exhibited pathological hemodynamics: elevated aneurysmal pressure (101.73 ± 0.28 vs. 100.59 ± 0.87 mmHg, p < 0.001), flow stasis (velocity: 5.53 ± 3.52 vs. 12.41 ± 3.44 cm/s, p < 0.001), reduced TAWSS (0.007 ± 0.004 vs. 0.03 ± 0.01 Pa, p < 0.001), and increased OSI (0.07 ± 0.04 vs. 0.01 ± 0.00) and RRT (12.73 ± 13.81 vs. 0.33 ± 0.11 /Pa, all p < 0.001). Perforator hemodynamics remained comparable to controls. Virtual reconstruction of BA normalized all aneurysmal parameters toward physiological levels (Post vs. Pre: all p < 0.001) without adversely affecting hemodynamics in the modeled PPs under the assumptions of the CFD framework. Strong correlations existed between BA volume and adverse hemodynamics, with therapeutic benefits approaching saturation at about 250 mm 3 . Conclusion: This in silico study demonstrates that perforator-sparing partial reconstruction can normalize VBD’s pathological hemodynamics without adversely affecting hemodynamics in the modeled PPs, and establishes a quantitative framework for future endovascular device development, though clinical translation requires validation through experimental models and prospective trials.
- Open Access
- 3 January 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-9
Analysis and prediction of subarachnoid hemorrhage burden in global, China, and Japan
Subarachnoid hemorrhage (SAH) remains a serious public health problem worldwide, especially in economically developed regions/countries. This study intends to thoroughly analyze the incidence, mortality, and disability-adjusted life years (DALYs) rate of SAH at the global, regional, and national levels. This study focused on the differences in SAH incidence between China and Japan from 1990 to 2019, and projected global, Chinese, and Japanese SAH incidence rates until 2030. Data on the disease burden owing to SAH from 1990 to 2019 were obtained from the Global Burden of Disease (GBD) Study 2019. linear regression analysis was used to calculate the estimated annual percentage change (EAPC) and linear regression method was used to calculate the average annual percentage change (AAPC). Bayesian age-period-cohort (BAPC) model was used to predict the disease burden from 2020 to 2030. Globally, age-standardised incidence, mortality, and DALYs rates was declined from 1990 to 2019. In 1990–2019, the incidence of SAH decreased in China, while it increased in Japan, especially among middle-aged and elderly women. Projections suggest that the global incidence of SAH will decrease by 2.06% in 2030, with an increase of 6.24% in China and 13.82% in Japan, with the highest increase among Japanese women being 16.19%. Global SAH incidence, mortality, and DALYs rates declined over the 1990–2019 period, with regional/national SAH mortality and DALYs rates negatively correlated with socio-demographic index (SDI), while SAH incidence was positively correlated with SDI. The incidence of SAH decreased in China and increased in Japan during this period. The predictions show that over the next 10 years, while the incidence of SAH continues to decline globally, the incidence of SAH in China and Japan has increased. Thus, SAH remains a serious disease burden that requires early intervention targeting risk factors and populations at risk that may have increased because of economic development.
- 3 January 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-9
Open AccessAnalysis and prediction of subarachnoid hemorrhage burden in global, China, and Japan
Subarachnoid hemorrhage (SAH) remains a serious public health problem worldwide, especially in economically developed regions/countries. This study intends to thoroughly analyze the incidence, mortality, and disability-adjusted life years (DALYs) rate of SAH at the global, regional, and national levels. This study focused on the differences in SAH incidence between China and Japan from 1990 to 2019, and projected global, Chinese, and Japanese SAH incidence rates until 2030. Data on the disease burden owing to SAH from 1990 to 2019 were obtained from the Global Burden of Disease (GBD) Study 2019. linear regression analysis was used to calculate the estimated annual percentage change (EAPC) and linear regression method was used to calculate the average annual percentage change (AAPC). Bayesian age-period-cohort (BAPC) model was used to predict the disease burden from 2020 to 2030. Globally, age-standardised incidence, mortality, and DALYs rates was declined from 1990 to 2019. In 1990–2019, the incidence of SAH decreased in China, while it increased in Japan, especially among middle-aged and elderly women. Projections suggest that the global incidence of SAH will decrease by 2.06% in 2030, with an increase of 6.24% in China and 13.82% in Japan, with the highest increase among Japanese women being 16.19%. Global SAH incidence, mortality, and DALYs rates declined over the 1990–2019 period, with regional/national SAH mortality and DALYs rates negatively correlated with socio-demographic index (SDI), while SAH incidence was positively correlated with SDI. The incidence of SAH decreased in China and increased in Japan during this period. The predictions show that over the next 10 years, while the incidence of SAH continues to decline globally, the incidence of SAH in China and Japan has increased. Thus, SAH remains a serious disease burden that requires early intervention targeting risk factors and populations at risk that may have increased because of economic development.
- Open Access
- 29 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7269
Correction: Gao et al. High Expression of PDK4 Could Play a Potentially Protective Role by Attenuating Oxidative Stress after Subarachnoid Hemorrhage. J. Clin. Med. 2022, 11, 3974
- 29 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7269
Open AccessCorrection: Gao et al. High Expression of PDK4 Could Play a Potentially Protective Role by Attenuating Oxidative Stress after Subarachnoid Hemorrhage. J. Clin. Med. 2022, 11, 3974
- 21 August 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (10) , 1071-1077
Half-dose ticagrelor versus standard-dose clopidogrel in a dual antiplatelet regimen for stent-assisted coiling or flow diversion of unruptured intracranial aneurysms: a cohort study
Background Intracranial hemorrhage is the major safety concern of standard-dose ticagrelor (90 mg twice daily) based dual antiplatelet therapy (DAPT). The bleeding avoidance strategy through dose de-escalation has been investigated in interventional cardiology. However, the preserved antithrombotic efficacy and better safety of half-dose (45 mg twice daily) ticagrelor remains unverified in patients undergoing stent-assist coiling (SAC) or flow diversion (FD) treating unruptured intracranial aneurysms (UIA). Methods A single-center, prospective, cohort study was conducted to compare DAPT with aspirin 100 mg daily plus half-dose ticagrelor vs standard-dose clopidogrel (75 mg daily) in UIA patients. The adenosine diphosphate inhibition (ADPi) rate was utilized to quantify the antagonization of adenosine diphosphate (ADP)-induced platelet aggregation. The patients were followed-up at 6 month after discharge. The primary efficacy outcome was the major adverse cardiovascular and cerebrovascular events (MACCE), and the primary safety outcome was major bleeding. The secondary outcome was minor hemorrhage. Results Our study included 322 UIA patients, of which 254 patients were eventually enrolled after propensity score matching. The ADPi of half-dose ticagrelor (51.56%±31.46%) was comparable (P=0.089) to that of clopidogrel (57.44%±22.76%). The outcomes were also comparable. Five (3.94%) patients in the ticagrelor group and eight (6.30%) patients in the clopidogrel group reported MACCE (P=0.393). One patient in the ticagrelor group was diagnosed with asymptomatic intracranial hemorrhage 1 month after stenting. There were 36 (28.35%) minor hemorrhagic events in the ticagrelor group and 35 (27.56%) in the clopidogrel group, (P=0.889). Conclusion Half-dose ticagrelor was effective and safe as a potential alternative to clopidogrel in the DAPT regimen for patients undergoing SAC/FD for UIA.
- 21 August 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (10) , 1071-1077
Half-dose ticagrelor versus standard-dose clopidogrel in a dual antiplatelet regimen for stent-assisted coiling or flow diversion of unruptured intracranial aneurysms: a cohort study
Background Intracranial hemorrhage is the major safety concern of standard-dose ticagrelor (90 mg twice daily) based dual antiplatelet therapy (DAPT). The bleeding avoidance strategy through dose de-escalation has been investigated in interventional cardiology. However, the preserved antithrombotic efficacy and better safety of half-dose (45 mg twice daily) ticagrelor remains unverified in patients undergoing stent-assist coiling (SAC) or flow diversion (FD) treating unruptured intracranial aneurysms (UIA). Methods A single-center, prospective, cohort study was conducted to compare DAPT with aspirin 100 mg daily plus half-dose ticagrelor vs standard-dose clopidogrel (75 mg daily) in UIA patients. The adenosine diphosphate inhibition (ADPi) rate was utilized to quantify the antagonization of adenosine diphosphate (ADP)-induced platelet aggregation. The patients were followed-up at 6 month after discharge. The primary efficacy outcome was the major adverse cardiovascular and cerebrovascular events (MACCE), and the primary safety outcome was major bleeding. The secondary outcome was minor hemorrhage. Results Our study included 322 UIA patients, of which 254 patients were eventually enrolled after propensity score matching. The ADPi of half-dose ticagrelor (51.56%±31.46%) was comparable (P=0.089) to that of clopidogrel (57.44%±22.76%). The outcomes were also comparable. Five (3.94%) patients in the ticagrelor group and eight (6.30%) patients in the clopidogrel group reported MACCE (P=0.393). One patient in the ticagrelor group was diagnosed with asymptomatic intracranial hemorrhage 1 month after stenting. There were 36 (28.35%) minor hemorrhagic events in the ticagrelor group and 35 (27.56%) in the clopidogrel group, (P=0.889). Conclusion Half-dose ticagrelor was effective and safe as a potential alternative to clopidogrel in the DAPT regimen for patients undergoing SAC/FD for UIA.
- Open Access
- 26 July 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1159958
Salvianolic acid B ameliorates neuroinflammation and neuronal injury via blocking NLRP3 inflammasome and promoting SIRT1 in experimental subarachnoid hemorrhage
The nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated immuno-inflammatory response plays a critical role in exacerbating early brain injury (EBI) after subarachnoid hemorrhage (SAH). Salvianolic acid B (SalB) has previously been shown to suppress neuroinflammatory responses in many disorders. Meanwhile, a previous study has demonstrated that SalB mitigated oxidative damage and neuronal degeneration in a prechiasmatic injection model of SAH. However, the therapeutic potential of SalB on immuno-inflammatory responses after SAH remains unclear. In the present study, we explored the therapeutic effects of SalB on neuroinflammatory responses in an endovascular perforation SAH model. We observed that SalB ameliorated SAH-induced functional deficits. Additionally, SalB significantly mitigated microglial activation, pro-inflammatory cytokines release, and neuronal injury. Mechanistically, SalB inhibited NLRP3 inflammasome activation and increased sirtuin 1 (SIRT1) expression after SAH. Administration of EX527, an inhibitor of SIRT1, abrogated the anti-inflammatory effects of SalB against SAH and further induced NLRP3 inflammasome activation. In contrast, MCC950, a potent and selective NLRP3 inflammasome inhibitor, reversed the detrimental effects of SIRT1 inhibition by EX527 on EBI. These results indicated that SalB effectively repressed neuroinflammatory responses and neuronal damage after SAH. The action of SalB appeared to be mediated by blocking NLRP3 inflammasome and promoting SIRT1 signaling.
- 26 July 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1159958
Open AccessSalvianolic acid B ameliorates neuroinflammation and neuronal injury via blocking NLRP3 inflammasome and promoting SIRT1 in experimental subarachnoid hemorrhage
The nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated immuno-inflammatory response plays a critical role in exacerbating early brain injury (EBI) after subarachnoid hemorrhage (SAH). Salvianolic acid B (SalB) has previously been shown to suppress neuroinflammatory responses in many disorders. Meanwhile, a previous study has demonstrated that SalB mitigated oxidative damage and neuronal degeneration in a prechiasmatic injection model of SAH. However, the therapeutic potential of SalB on immuno-inflammatory responses after SAH remains unclear. In the present study, we explored the therapeutic effects of SalB on neuroinflammatory responses in an endovascular perforation SAH model. We observed that SalB ameliorated SAH-induced functional deficits. Additionally, SalB significantly mitigated microglial activation, pro-inflammatory cytokines release, and neuronal injury. Mechanistically, SalB inhibited NLRP3 inflammasome activation and increased sirtuin 1 (SIRT1) expression after SAH. Administration of EX527, an inhibitor of SIRT1, abrogated the anti-inflammatory effects of SalB against SAH and further induced NLRP3 inflammasome activation. In contrast, MCC950, a potent and selective NLRP3 inflammasome inhibitor, reversed the detrimental effects of SIRT1 inhibition by EX527 on EBI. These results indicated that SalB effectively repressed neuroinflammatory responses and neuronal damage after SAH. The action of SalB appeared to be mediated by blocking NLRP3 inflammasome and promoting SIRT1 signaling.
- Open Access
- 20 July 2023
- Published by Medknow in Neural Regeneration Research
- Vol. 19 (4) , 825-832
Mitochondrial dysfunction and quality control lie at the heart of subarachnoid hemorrhage
The dramatic increase in intracranial pressure after subarachnoid hemorrhage leads to a decrease in cerebral perfusion pressure and a reduction in cerebral blood flow. Mitochondria are directly affected by direct factors such as ischemia, hypoxia, excitotoxicity, and toxicity of free hemoglobin and its degradation products, which trigger mitochondrial dysfunction. Dysfunctional mitochondria release large amounts of reactive oxygen species, inflammatory mediators, and apoptotic proteins that activate apoptotic pathways, further damaging cells. In response to this array of damage, cells have adopted multiple mitochondrial quality control mechanisms through evolution, including mitochondrial protein quality control, mitochondrial dynamics, mitophagy, mitochondrial biogenesis, and intercellular mitochondrial transfer, to maintain mitochondrial homeostasis under pathological conditions. Specific interventions targeting mitochondrial quality control mechanisms have emerged as promising therapeutic strategies for subarachnoid hemorrhage. This review provides an overview of recent research advances in mitochondrial pathophysiological processes after subarachnoid hemorrhage, particularly mitochondrial quality control mechanisms. It also presents potential therapeutic strategies to target mitochondrial quality control in subarachnoid hemorrhage.
- 20 July 2023
- Published by Medknow in Neural Regeneration Research
- Vol. 19 (4) , 825-832
Open AccessMitochondrial dysfunction and quality control lie at the heart of subarachnoid hemorrhage
The dramatic increase in intracranial pressure after subarachnoid hemorrhage leads to a decrease in cerebral perfusion pressure and a reduction in cerebral blood flow. Mitochondria are directly affected by direct factors such as ischemia, hypoxia, excitotoxicity, and toxicity of free hemoglobin and its degradation products, which trigger mitochondrial dysfunction. Dysfunctional mitochondria release large amounts of reactive oxygen species, inflammatory mediators, and apoptotic proteins that activate apoptotic pathways, further damaging cells. In response to this array of damage, cells have adopted multiple mitochondrial quality control mechanisms through evolution, including mitochondrial protein quality control, mitochondrial dynamics, mitophagy, mitochondrial biogenesis, and intercellular mitochondrial transfer, to maintain mitochondrial homeostasis under pathological conditions. Specific interventions targeting mitochondrial quality control mechanisms have emerged as promising therapeutic strategies for subarachnoid hemorrhage. This review provides an overview of recent research advances in mitochondrial pathophysiological processes after subarachnoid hemorrhage, particularly mitochondrial quality control mechanisms. It also presents potential therapeutic strategies to target mitochondrial quality control in subarachnoid hemorrhage.
- Open Access
- 6 February 2023
- Published by Wiley in Disease Markers
- Vol. 2023, 1-10
Peroxiredoxin 2 Is a Potential Objective Indicator for Severity and the Clinical Status of Subarachnoid Hemorrhage Patients
Purpose. We have demonstrated that peroxiredoxin 2 (Prx2) released from lytic erythrocytes and damaged neurons into the subarachnoid space could activate microglia and then result in neuronal apoptosis. In this study, we tested the possibility of using Prx2 as an objective indicator for severity of the subarachnoid hemorrhage (SAH) and the clinical status of the patient. Materials and Methods. SAH patients were prospectively enrolled and followed up for 3 months. Cerebrospinal fluid (CSF) and blood samples were collected 0-3 and 5-7 days after SAH onset. The levels of Prx2 in the CSF and the blood were measured by an enzyme-linked immunosorbent assay (ELISA). We used Spearman’s rank coefficient to assess the correlation between Prx2 and the clinical scores. Receiver operating characteristic (ROC) curves were used for Prx2 levels to predict the outcome of SAH by calculating the area under the curve (AUC). Unpaired Student’s -test was used to analyze the differences in continuous variables across cohorts. Results. Prx2 levels in the CSF increased after onset while those in the blood decreased. Existing data showed that Prx2 levels within 3 days in the CSF after SAH were positively correlated with the Hunt-Hess score ( , ). Patients with CVS had higher levels of Prx2 in their CSF within 5-7 days after onset. Prx2 levels in the CSF within 5-7 days can be used as a predictor of prognosis. The ratio of Prx2 in the CSF and the blood within 3 days of onset was positively correlated with the Hunt-Hess score and negatively correlated with Glasgow Outcome Scale (GOS; , ). Conclusion. We found that the levels of Prx2 in the CSF and the ratio of Prx2 in the CSF and the blood within 3 days of onset can be used as a biomarker to detect the severity of the disease and the clinical status of the patient.
- 6 February 2023
- Published by Wiley in Disease Markers
- Vol. 2023, 1-10
Open AccessPeroxiredoxin 2 Is a Potential Objective Indicator for Severity and the Clinical Status of Subarachnoid Hemorrhage Patients
Purpose. We have demonstrated that peroxiredoxin 2 (Prx2) released from lytic erythrocytes and damaged neurons into the subarachnoid space could activate microglia and then result in neuronal apoptosis. In this study, we tested the possibility of using Prx2 as an objective indicator for severity of the subarachnoid hemorrhage (SAH) and the clinical status of the patient. Materials and Methods. SAH patients were prospectively enrolled and followed up for 3 months. Cerebrospinal fluid (CSF) and blood samples were collected 0-3 and 5-7 days after SAH onset. The levels of Prx2 in the CSF and the blood were measured by an enzyme-linked immunosorbent assay (ELISA). We used Spearman’s rank coefficient to assess the correlation between Prx2 and the clinical scores. Receiver operating characteristic (ROC) curves were used for Prx2 levels to predict the outcome of SAH by calculating the area under the curve (AUC). Unpaired Student’s -test was used to analyze the differences in continuous variables across cohorts. Results. Prx2 levels in the CSF increased after onset while those in the blood decreased. Existing data showed that Prx2 levels within 3 days in the CSF after SAH were positively correlated with the Hunt-Hess score ( , ). Patients with CVS had higher levels of Prx2 in their CSF within 5-7 days after onset. Prx2 levels in the CSF within 5-7 days can be used as a predictor of prognosis. The ratio of Prx2 in the CSF and the blood within 3 days of onset was positively correlated with the Hunt-Hess score and negatively correlated with Glasgow Outcome Scale (GOS; , ). Conclusion. We found that the levels of Prx2 in the CSF and the ratio of Prx2 in the CSF and the blood within 3 days of onset can be used as a biomarker to detect the severity of the disease and the clinical status of the patient.
- Open Access
- 30 November 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 3550204
Pterostilbene Attenuates Subarachnoid Hemorrhage‐Induced Brain Injury through the SIRT1‐Dependent Nrf2 Signaling Pathway
Neuroinflammatory injury, oxidative insults, and neuronal apoptosis are major causes of poor outcomes after subarachnoid hemorrhage (SAH). Pterostilbene (PTE), an analog of resveratrol, has been verified as a potent sirtuin 1 (SIRT1) activator. However, the beneficial actions of PTE on SAH‐induced brain injury and whether PTE regulates SIRT1 signaling after SAH remain unknown. We first evaluated the dose‐response influence of PTE on early brain impairment after SAH. In addition, EX527 was administered to suppress SIRT1 signaling. The results revealed that PTE significantly attenuated microglia activation, oxidative insults, neuronal damage, and early neurological deterioration. Mechanistically, PTE effectively enhanced SIRT1 expression and promoted nuclear factor‐erythroid 2‐related factor 2 (Nrf2) accumulation in nuclei. Furthermore, EX527 pretreatment distinctly repressed PTE‐induced SIRT1 and Nrf2 activation and deteriorated these beneficial outcomes. In all, our study provides the evidence that PTE protects against SAH insults by activating SIRT1‐dependent Nrf2 signaling pathway. PTE might be a therapeutic alternative for SAH.
- 30 November 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 3550204
Open AccessPterostilbene Attenuates Subarachnoid Hemorrhage‐Induced Brain Injury through the SIRT1‐Dependent Nrf2 Signaling Pathway
Neuroinflammatory injury, oxidative insults, and neuronal apoptosis are major causes of poor outcomes after subarachnoid hemorrhage (SAH). Pterostilbene (PTE), an analog of resveratrol, has been verified as a potent sirtuin 1 (SIRT1) activator. However, the beneficial actions of PTE on SAH‐induced brain injury and whether PTE regulates SIRT1 signaling after SAH remain unknown. We first evaluated the dose‐response influence of PTE on early brain impairment after SAH. In addition, EX527 was administered to suppress SIRT1 signaling. The results revealed that PTE significantly attenuated microglia activation, oxidative insults, neuronal damage, and early neurological deterioration. Mechanistically, PTE effectively enhanced SIRT1 expression and promoted nuclear factor‐erythroid 2‐related factor 2 (Nrf2) accumulation in nuclei. Furthermore, EX527 pretreatment distinctly repressed PTE‐induced SIRT1 and Nrf2 activation and deteriorated these beneficial outcomes. In all, our study provides the evidence that PTE protects against SAH insults by activating SIRT1‐dependent Nrf2 signaling pathway. PTE might be a therapeutic alternative for SAH.
- 25 November 2022
- Published by Elsevier in World Neurosurgery
- Vol. 170, e755-e765
Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Unruptured Intracranial Aneurysm Treated with Stent-Assisted Coil Embolization: A Single-Center Cohort Study
- 25 November 2022
- Published by Elsevier in World Neurosurgery
- Vol. 170, e755-e765
Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Unruptured Intracranial Aneurysm Treated with Stent-Assisted Coil Embolization: A Single-Center Cohort Study